Yale scientists show that Biotin and Chromium Picolinate improve blood sugar control in diabetics already on medication with poor blood sugar control
Researchers at the Section of Cardiovascular Medicine, Yale University School
of Medicine state that previous studies show that the combination of Chromium
Picolinate and Biotin improve the uptake and storage of glucose into muscle
and also increase the disposal of glucose.
In this human clinical pilot study the two nutrients were tested in diabetics
with poor sugar control despite the use of medication to treat their diabetes.
43 diabetic patients on medication whose blood sugar still ranged over 200 two
hours after meals and had an elevated A1C of over 7.0 (a 3 month panoramic view
of blood sugar control; the normal value is under 6.0) received either 600 mcg
of Chromium Picolinate with 2000mcg of Biotin each day or an inactive placebo
for comparisons sake in addition to their regular medication. After 4-weeks
the amount of glucose in the blood 2 hours after meals decreased by about 10%
on the supplements compared to placebo (who actually experienced a 5% increase
in the level of blood sugar two hours after eating). Fructosamine, a measure
of blood sugar control over the past two weeks also improved and triglyceride
levels dropped. The supplements were judged to be safe and lacking in side effects.
The study is published in the December 2006 issue of the journal Diabetes
Technology and Therapeutics.
Biotin with Chromium improve blood sugar, cholesterol and triglycerides
in diabetics even if they are on statin drugs
Researchers at Alpha Therapy in Corpus Christi gave diabetics either placebo
or a combination of Biotin with Chromium Picolinate for 90 days in this clinical
trial that included 348 diabetics. The nutrients lowered blood sugar and A1C
significantly compared to placebo. In patients with diabetes and high cholesterol
the nutrients significantly lowered total cholesterol and LDL-cholesterol levels
compared to placebo. The nutrients also decreased triglycerides and AIC compared
to placebo. This reduction in blood fats occurred even in patients taking statin
drugs for their cholesterol. The supplements side effects were as infrequent
as placebo meaning they were safe and easily tolerated. The study is published
in the spring 2007 issue of the Journal of the Cardiometabolic Syndrome.